Lifecore Biomedical merger receives early termination of US antitrust waiting period

• Lifecore Biomedical's merger with Lifecore cleared a closing condition on November 4, 2026, when U.S. antitrust agencies ended the waiting period early.
• Under the September 27, 2026, merger agreement, the company will become a wholly owned subsidiary of Lifecore.
• Completion remains subject to other closing conditions, including stockholder adoption of the merger agreement at a special meeting.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lifecore Biomedical Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001005286-26-000049), on November 05, 2026, and is solely responsible for the information contained therein.